10.54

4.64% 0.4881

Zevra Therapeutics Inc (ZVRA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Zevra Therapeutics Inc stock is traded at $10.54, with a volume of 470.56K. It is up +4.64% in the last 24 hours and up +11.87% over the past month. Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Previous Close:

$10.05

Open:

$10.16

24h Volume:

470.56K

Relative Volume:

0.48

Market Cap:

$623.66M

Revenue:

$106.47M

Net Income/Loss:

$82.89M

P/E Ratio:

7.0555

EPS:

1.4936

Net Cash Flow:

$-2.43M

1W Performance:

+6.22%

1M Performance:

+11.87%

6M Performance:

+4.43%

1Y Performance:

+31.45%

1-Day Range:

$10.16

$10.66

1-Week Range:

$9.475

$10.66

52-Week Range:

$7.16

$13.16

Zevra Therapeutics Inc Stock (ZVRA) Company Profile

Name

Zevra Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (622)

Phone

(888) 958-1253

Address

101 FEDERAL STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

ZVRA's Discussions on Twitter

Compare ZVRA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZVRA Zevra Therapeutics Inc	10.55	594.10M	106.47M	82.89M	-2.43M	1.4936
VRTX Vertex Pharmaceuticals Inc	418.85	109.34B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	702.96	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	796.00	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	300.23	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	294.41	33.02B	5.36B	287.73M	924.18M	2.5229

Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Initiated	BTIG Research	Buy
Jul-02-25	Initiated	H.C. Wainwright	Buy
Jan-08-25	Resumed	Cantor Fitzgerald	Overweight
Oct-07-24	Initiated	Guggenheim	Buy
Sep-24-24	Initiated	JMP Securities	Mkt Outperform
Sep-24-24	Reiterated	Maxim Group	Buy
Apr-02-24	Reiterated	Maxim Group	Buy
Mar-12-24	Initiated	William Blair	Outperform
Mar-17-23	Initiated	Maxim Group	Buy

View All

Zevra Therapeutics Inc Stock (ZVRA) Latest News

May 04, 2026

MSN Money - MSN

May 04, 2026

May 01, 2026

ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill

May 01, 2026

Apr 29, 2026

Zevra Therapeutics (ZVRA) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat

Apr 29, 2026

Apr 28, 2026

ZVRA Technical Analysis | Trend, Signals & Chart Patterns | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill

Apr 28, 2026

Apr 27, 2026

ZVRA stock soars on upbeat Q4 results, optimism for EMA approval of Niemann-Pick disease treatment - MSN

Apr 27, 2026

Zevra Therapeutics schedules first quarter 2026 results release and webcast for May 6 - Traders Union

Apr 22, 2026

Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call - The Globe and Mail

Apr 22, 2026

Zevra to release first-quarter results after market close May 6 - Stock Titan

Apr 22, 2026

Apr 20, 2026